Do analysts recommend MOR or ZVRA?

Zevra Therapeutics has a consensus price target of $27.14, indicating a potential upside of 126.00%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Zevra Therapeutics is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Zevra Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90

Is MOR or ZVRA more profitable?

Zevra Therapeutics has a net margin of 42.82% compared to MorphoSys' net margin of -226.79%. Zevra Therapeutics' return on equity of 54.54% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Zevra Therapeutics 42.82% 54.54% 34.15%

Does the media prefer ZVRA or ATAI?

In the previous week, Atai Beckley had 1 more articles in the media than Zevra Therapeutics. MarketBeat recorded 4 mentions for Atai Beckley and 3 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 1.77 beat Atai Beckley's score of 0.75 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SUPN or ZVRA?

In the previous week, Supernus Pharmaceuticals and Supernus Pharmaceuticals both had 3 articles in the media. Zevra Therapeutics' average media sentiment score of 1.77 beat Supernus Pharmaceuticals' score of 1.04 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Zevra Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor BHC or ZVRA?

In the previous week, Bausch Health Cos had 1 more articles in the media than Zevra Therapeutics. MarketBeat recorded 4 mentions for Bausch Health Cos and 3 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 1.77 beat Bausch Health Cos' score of 1.04 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch Health Cos 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor ZVRA or MLYS?

In the previous week, Mineralys Therapeutics had 7 more articles in the media than Zevra Therapeutics. MarketBeat recorded 10 mentions for Mineralys Therapeutics and 3 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 1.77 beat Mineralys Therapeutics' score of 1.10 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Mineralys Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Zevra Therapeutics (ZVRA) Competitors

$12.01 -0.05 (-0.41%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$12.01 0.00 (0.00%)

As of 09/11/2026 07:30 PM Eastern

Compare

ZVRA vs. MOR, ATAI, SUPN, BHC, and MLYS

Should you buy Zevra Therapeutics stock or one of its competitors? Zevra Therapeutics's main competitors and comparable companies include MorphoSys (MOR), Atai Beckley (ATAI), Supernus Pharmaceuticals (SUPN), Bausch Health Cos (BHC), and Mineralys Therapeutics (MLYS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Zevra Therapeutics compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Zevra Therapeutics (NASDAQ:ZVRA) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Zevra Therapeutics has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Zevra Therapeutics	$136.07M	5.24	$83.23M	$0.92	13.05

18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 3.7% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zevra Therapeutics has a net margin of 42.82% compared to MorphoSys' net margin of -226.79%. Zevra Therapeutics' return on equity of 54.54% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Zevra Therapeutics	42.82%	54.54%	34.15%

In the previous week, Zevra Therapeutics had 3 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Zevra Therapeutics and 0 mentions for MorphoSys. Zevra Therapeutics' average media sentiment score of 1.77 beat MorphoSys' score of 0.00 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Zevra Therapeutics	Very Positive

MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market.

Zevra Therapeutics has a consensus price target of $27.14, indicating a potential upside of 126.00%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Zevra Therapeutics is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Summary

Zevra Therapeutics beats MorphoSys on 13 of the 16 factors compared between the two stocks.

How does Zevra Therapeutics compare to Atai Beckley?

Zevra Therapeutics (NASDAQ:ZVRA) and Atai Beckley (NASDAQ:ATAI) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Atai Beckley shares are owned by institutional investors. 3.7% of Zevra Therapeutics shares are owned by insiders. Comparatively, 19.8% of Atai Beckley shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Zevra Therapeutics has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$136.07M	5.24	$83.23M	$0.92	13.05
Atai Beckley	$4.47M	609.54	-$660.05M	-$2.18	N/A

Zevra Therapeutics presently has a consensus target price of $27.14, indicating a potential upside of 126.00%. Atai Beckley has a consensus target price of $10.56, indicating a potential upside of 43.62%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Zevra Therapeutics is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Atai Beckley	1 Sell rating(s)	14 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.06

Zevra Therapeutics has a net margin of 42.82% compared to Atai Beckley's net margin of -14,938.36%. Zevra Therapeutics' return on equity of 54.54% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	42.82%	54.54%	34.15%
Atai Beckley	-14,938.36%	-88.30%	-58.88%

Zevra Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

In the previous week, Atai Beckley had 1 more articles in the media than Zevra Therapeutics. MarketBeat recorded 4 mentions for Atai Beckley and 3 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 1.77 beat Atai Beckley's score of 0.75 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zevra Therapeutics beats Atai Beckley on 12 of the 17 factors compared between the two stocks.

How does Zevra Therapeutics compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Zevra Therapeutics (NASDAQ:ZVRA) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

35.0% of Zevra Therapeutics shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 3.7% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Zevra Therapeutics has a net margin of 42.82% compared to Supernus Pharmaceuticals' net margin of -13.23%. Zevra Therapeutics' return on equity of 54.54% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Zevra Therapeutics	42.82%	54.54%	34.15%

In the previous week, Supernus Pharmaceuticals and Supernus Pharmaceuticals both had 3 articles in the media. Zevra Therapeutics' average media sentiment score of 1.77 beat Supernus Pharmaceuticals' score of 1.04 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Zevra Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Zevra Therapeutics has lower revenue, but higher earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.37	-$38.55M	-$1.92	N/A
Zevra Therapeutics	$136.07M	5.24	$83.23M	$0.92	13.05

Supernus Pharmaceuticals has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Supernus Pharmaceuticals currently has a consensus price target of $62.83, indicating a potential upside of 50.90%. Zevra Therapeutics has a consensus price target of $27.14, indicating a potential upside of 126.00%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Zevra Therapeutics is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Summary

Zevra Therapeutics beats Supernus Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

How does Zevra Therapeutics compare to Bausch Health Cos?

Bausch Health Cos (NYSE:BHC) and Zevra Therapeutics (NASDAQ:ZVRA) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by company insiders. Comparatively, 3.7% of Zevra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Zevra Therapeutics has a net margin of 42.82% compared to Bausch Health Cos' net margin of -10.12%. Zevra Therapeutics' return on equity of 54.54% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-10.12%	-561.95%	6.31%
Zevra Therapeutics	42.82%	54.54%	34.15%

In the previous week, Bausch Health Cos had 1 more articles in the media than Zevra Therapeutics. MarketBeat recorded 4 mentions for Bausch Health Cos and 3 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 1.77 beat Bausch Health Cos' score of 1.04 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch Health Cos	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zevra Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Bausch Health Cos has higher revenue and earnings than Zevra Therapeutics. Bausch Health Cos is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.21	$157M	-$2.96	N/A
Zevra Therapeutics	$136.07M	5.24	$83.23M	$0.92	13.05

Bausch Health Cos has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market.

Bausch Health Cos currently has a consensus target price of $8.00, suggesting a potential upside of 36.64%. Zevra Therapeutics has a consensus target price of $27.14, suggesting a potential upside of 126.00%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Zevra Therapeutics is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90

Summary

Zevra Therapeutics beats Bausch Health Cos on 11 of the 16 factors compared between the two stocks.

How does Zevra Therapeutics compare to Mineralys Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Mineralys Therapeutics (NASDAQ:MLYS) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

Zevra Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Mineralys Therapeutics has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

Zevra Therapeutics has a net margin of 42.82% compared to Mineralys Therapeutics' net margin of 0.00%. Zevra Therapeutics' return on equity of 54.54% beat Mineralys Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	42.82%	54.54%	34.15%
Mineralys Therapeutics	N/A	-57.97%	-54.15%

In the previous week, Mineralys Therapeutics had 7 more articles in the media than Zevra Therapeutics. MarketBeat recorded 10 mentions for Mineralys Therapeutics and 3 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 1.77 beat Mineralys Therapeutics' score of 1.10 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Mineralys Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 3.7% of Zevra Therapeutics shares are owned by company insiders. Comparatively, 18.9% of Mineralys Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Zevra Therapeutics has higher revenue and earnings than Mineralys Therapeutics. Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$136.07M	5.24	$83.23M	$0.92	13.05
Mineralys Therapeutics	N/A	N/A	-$154.65M	-$4.24	N/A

Zevra Therapeutics presently has a consensus price target of $27.14, indicating a potential upside of 126.00%. Mineralys Therapeutics has a consensus price target of $48.80, indicating a potential upside of 73.05%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Zevra Therapeutics is more favorable than Mineralys Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
Mineralys Therapeutics	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

Zevra Therapeutics beats Mineralys Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Zevra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZVRA vs. The Competition

Export

Metric	Zevra Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$716.17M	$12.44B	$7.13B	$12.72B
Dividend Yield	N/A	2.62%	2.56%	11.15%
P/E Ratio	13.05	799.75	275.24	25.29
Price / Sales	5.24	763.36	655.99	98.94
Price / Cash	12.75	89.25	77.04	51.44
Price / Book	4.37	10.39	10.33	6.20
Net Income	$83.23M	$2.85B	$3.50B	$358.50M
7 Day Performance	-3.15%	-3.61%	-3.32%	-2.35%
1 Month Performance	4.98%	0.86%	-0.41%	-2.77%
1 Year Performance	54.97%	3.47%	19.21%	7.63%

Zevra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZVRA Zevra Therapeutics	4.8271 of 5 stars	$12.01 -0.4%	$27.14 +126.0%	+51.1%	$716.17M	$136.07M	13.05	20	Positive News
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730
ATAI Atai Beckley	2.7613 of 5 stars	$7.39 +0.7%	$10.56 +42.8%	+59.4%	$2.72B	$4.09M	N/A	80	News Coverage Analyst Upgrade Options Volume
SUPN Supernus Pharmaceuticals	3.5755 of 5 stars	$43.53 -1.0%	$62.83 +44.3%	-10.8%	$2.56B	$718.95M	N/A	580	Positive News
BHC Bausch Health Cos	2.8859 of 5 stars	$6.54 -3.3%	$8.00 +22.3%	-19.4%	$2.53B	$10.85B	N/A	20,300	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZVRA) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zevra Therapeutics (ZVRA) Competitors

ZVRA vs. MOR, ATAI, SUPN, BHC, and MLYS

How does Zevra Therapeutics compare to MorphoSys?

Summary

How does Zevra Therapeutics compare to Atai Beckley?

Summary

How does Zevra Therapeutics compare to Supernus Pharmaceuticals?

Summary

How does Zevra Therapeutics compare to Bausch Health Cos?

Summary

How does Zevra Therapeutics compare to Mineralys Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA vs. The Competition

Zevra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zevra Therapeutics (ZVRA) Competitors

ZVRA vs. MOR, ATAI, SUPN, BHC, and MLYS

How does Zevra Therapeutics compare to MorphoSys?

Which has stronger earnings and valuation, MOR or ZVRA?

Do insiders & institutionals believe in MOR or ZVRA?

Is MOR or ZVRA more profitable?

Does the media favor MOR or ZVRA?

Which has more volatility and risk, MOR or ZVRA?

Do analysts recommend MOR or ZVRA?

Summary

How does Zevra Therapeutics compare to Atai Beckley?

Do institutionals and insiders have more ownership in ZVRA or ATAI?

Which has preferable valuation and earnings, ZVRA or ATAI?

Do analysts prefer ZVRA or ATAI?

Is ZVRA or ATAI more profitable?

Which has more risk & volatility, ZVRA or ATAI?

Does the media prefer ZVRA or ATAI?

Summary

How does Zevra Therapeutics compare to Supernus Pharmaceuticals?

Do institutionals & insiders hold more shares of SUPN or ZVRA?

Is SUPN or ZVRA more profitable?

Does the media favor SUPN or ZVRA?

Which has higher earnings and valuation, SUPN or ZVRA?

Which has more risk & volatility, SUPN or ZVRA?

Do analysts rate SUPN or ZVRA?

Summary

How does Zevra Therapeutics compare to Bausch Health Cos?

Do insiders & institutionals have more ownership in BHC or ZVRA?

Is BHC or ZVRA more profitable?

Does the media favor BHC or ZVRA?

Which has higher earnings & valuation, BHC or ZVRA?

Which has more risk & volatility, BHC or ZVRA?

Do analysts rate BHC or ZVRA?

Summary

How does Zevra Therapeutics compare to Mineralys Therapeutics?

Which has more risk and volatility, ZVRA or MLYS?

Is ZVRA or MLYS more profitable?

Does the media favor ZVRA or MLYS?

Do insiders and institutionals believe in ZVRA or MLYS?

Which has stronger earnings & valuation, ZVRA or MLYS?

Do analysts recommend ZVRA or MLYS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZVRA vs. The Competition

Zevra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools